Keita Miura, Takehito Shukuya, Naoki Furuya, Ryo Morita, Akira Kisohara, Atsuto Mouri, Satoshi Watanabe, Hisashi Tanaka, Aya Hirata, Taiki Hakozaki, et al. Impact of Cachexia and First-Line Systemic Therapy for Previously Untreated Advanced Non-Small Cell Lung Cancer: NEJ050A. Journal of cachexia, sarcopenia and muscle. 2024
Motohiko Yamazaki, Satoshi Watanabe, Masaki Tominaga, Takuya Yagi, Yukari Goto, Naohiro Yanagimura, Masashi Arita, Aya Ohtsubo, Tomohiro Tanaka, Koichiro Nozaki, et al. 18F-FDG-PET/CT Uptake by Noncancerous Lung as a Predictor of Interstitial Lung Disease Induced by Immune Checkpoint Inhibitors. Academic radiology. 2024
Tetsuhiko Asao, Takehito Shukuya, Kohei Uemura, Rui Kitadai, Gaku Yamamoto, Atsuto Mouri, Meiyo Tamaoka, Ryosuke Imai, Yoko Tsukita, Kazutoshi Isobe, et al. Risk and survival of patients with non-small cell lung cancer and pre-existing autoimmune disorders receiving immune checkpoint blockade therapy: Survival analysis with inverse probability weighting from a nationwide, multi-institutional, retrospective study (NEJ047). Lung cancer (Amsterdam, Netherlands). 2024. 194. 107894-107894
Naohiro Yanagimura, Satoshi Watanabe, Toshiaki Kikuchi. Combined PARP and PD-L1 inhibition: a promising treatment option for relapsed small-cell lung cancer. Journal of thoracic disease. 2024. 16. 6. 4075-4078
Satoshi Watanabe, Toshiaki Kikuchi. Does Autoimmune Response Against Surfactant Protein Cause Interstitial Lung Disease?. American journal of respiratory and critical care medicine. 2024
日本臨床腫瘍学会
, International association for the study of lung cancer
, American association for cancer research
, 日本癌学会
, 日本呼吸器内視鏡学会
, 日本肺癌学会
, 日本呼吸器学会
, 日本内科学会